Showing 5151-5160 of 5909 results for "".
- Prevent Blindness Unveils New Brand Identity, Logo and Websitehttps://modernod.com/news/prevent-blindness-unveils-new-brand-identity-logo-and-website/2477772/Prevent Blindness announced the launch of its new brand identity, logo, and website. The launch coincides with the organization’s new “Be a Visionary” campaign: a call to action to join in the sight-saving efforts of Prevent Blindness. The new identity is designed to refl
- Johnson & Johnson Vision Announces Global Initiatives to Support Eye Care Professionals and Patients During COVID-19 and Beyondhttps://modernod.com/news/johnson-johnson-vision-announces-global-initiatives-to-support-eye-care-professionals-and-patients-during-covid-19-and-beyond/2477770/Johnson & Johnson Vision is deploying solutions around the world to help address the challenges facing eye care professionals (ECPs) and their patients amid the COVID-19 pandemic. These support the broader efforts that Johnson & Johnson is taking to curb the crisis, including development
- ECPs Can Now Access Online Training to Certify to Prescribe CooperVision’s Brilliant Futures Myopia Management Programhttps://modernod.com/news/ecps-can-now-access-online-training-to-certify-to-prescribe-coopervisions-brilliant-futures-myopia-management-program/2477762/This month, CooperVision unveiled an online training curriculum so eye care professionals (ECPs) can certify to prescribe the Brilliant Futures Myopia Management Program featuring MiSight 1 day contact lenses. CooperVision will continue outreach to ECPs who have experience with pediatric populati
- The Vision Council Releases April COVID-19 Optical Impact Consumer Studyhttps://modernod.com/news/the-vision-council-releases-april-covid-19-optical-impact-consumer-study/2477763/The Vision Council has released the results of the April COVID-19 Optical Impact Consumer Study. The study, which launched in February and has continued since then as part of The Vision Council’s monthly VisionWatch consumer survey, gauges consumers’ level of concern about the COVID-19 pandemic a
- Ocular Therapeutix Announces First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI For Treatment of Dry Eye Diseasehttps://modernod.com/news/ocular-therapeutix-announces-first-patient-dosed-in-phase-1-clinical-trial-of-otx-csi-for-treatment-of-dry-eye-disease/2477754/Ocular Therapeutix announced that it has dosed the first patients in its phase 1 clinical trial of OTX-CSI (cyclosporine intracanalicular insert) for the treatment of dry eye disease (DED). “We are pleased to be advancing OTX-CSI in the chronic treatment of dry eye disease,” Michael Goldst
- Regeneron CEO: Manufacturing Not Up to Snuff for COVID-19 Vaccines, Therapieshttps://modernod.com/news/regeneron-ceo-manufacturing-not-up-to-snuff-for-covid-19-vaccines-therapies/2477753/Regeneron has been at the forefront of the COVID-19 fight for months with partnered med Kevzara in clinical trials and an antibody cocktail in development. But success in the clinic means nothing if drugmakers can’t produce a therapy or vaccine fast enough—and the company’s helmsman i
- Novavax Granted Up to $384 Million in New CEPI Funding for COVID-19 Vaccine Candidatehttps://modernod.com/news/novavax-granted-up-to-384-million-in-new-cepi-funding-for-covid-19-vaccine-candidate/2477747/Novavax announced that the Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $384 million of additional funding, on top of $4 million it invested in March, to advance clinical development of the company’s vaccine candidate NVX-CoV2373 against SARS-CoV-2. In Ap
- Stoke Therapeutics Presents Preclinical Data on Potential Treatment For Inherited Optic Nerve Disorderhttps://modernod.com/news/stoke-therapeutics-presents-preclinical-data-on-potential-treatment-for-inherited-optic-nerve-disorder/2477751/Stoke Therapeutics announced new preclinical data demonstrating in-vitro and in-vivo target engagement and protein upregulation in OPA1 protein-deficient cells. OPA1 protein deficiency is the primary cause of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorde
- Tearlab Acquired by Accelmed Partners for $25 Millionhttps://modernod.com/news/tearlab-acquired-by-accelmed-partners-for-25-million/2477742/Private equity firm Accelmed Partners II (AP-II) has agreed to acquire TearLab for $25 million. The payment, which will be made over two tranches, will result in TearLab delisting from the “over the counter” OTCQB mar
- Doximity Enters Telemedicine With Launch of Dialer Videohttps://modernod.com/news/doximity-enters-telemedicine-with-launch-of-dialer-video/2477732/Doximity announced the launch of Doximity Dialer Video, the company’s first telemedicine offering. With one click, Doximity Dialer Video lets doctors video call their patients, in an encrypted environment that complies with HIPAA privacy regulations. The new tool works with a doctor’s personal iO